Buyout vote looming, Celgene files for ozanimod OK (again), with a multibillion-dollar bet riding on every step
It took more than a year, but Celgene has managed to re-file its application for ozanimod a few days ahead of the end of Q1, as it said it would.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
